Monopar Therapeutics Inc. (MNPR) announced the pricing of its public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of about $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the company.
The offering is expected to close on October 30, 2024.
Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering.
Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.
Monopar Therapeutics plans to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product and working capital.
MNPR closed Monday's regular trading at $17.83 up $0.90 or 5.32%. But in the after-hours trading the stock dropped $2.73 or 15.31%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.